Journal of Medicinal Chemistry · 2024 · 12 citations · 30 references
Veterinary MedicineMedicinal ChemistryPharmacologyDrug DiscoveryInflammationSepsisAnti-inflammatory PharmacologyCytokine BiologyInflammation PharmacologyInflammatory SignalingInnate Immune Signaling PathwaysSepsis PathophysiologyHepatoprotective AgentsNf-κb SignalingNitric OxideNitric Oxide ProductionNuclear Factor Kappa B SignalingSepsis-associated InflammationSepsis-associated Lung InjurySepsis-induced Organ Failure
NIK plays a crucial role in the noncanonical NF-κB signaling pathway associated with diverse inflammatory and autoimmune diseases. Our study presents compound 54, a novel NIK inhibitor, designed through a structure-based scaffold-hopping approach from the previously identified B022. Compound 54 demonstrates remarkable selectivity and potency against NIK both in vitro and in vivo, effectively suppressing pro-inflammatory cytokines and nitric oxide production. In mouse models, compound 54 protected against LPS-induced systemic sepsis, reducing AST, ALT, and AKP liver injury markers. Additionally, it also attenuates sepsis-induced lung and kidney damage. Mechanistically, compound 54 blocks the noncanonical NF-κB signaling pathway by targeting NIK, preventing p100 to p52 processing. This work reveals a novel class of NIK inhibitors with significant potential for sepsis therapy.
30
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Steven M. Opal, Charles J. Fisher, Jean-François Dhainaut et al. · Critical Care Medicine · 1997 · 863 citations
Edward Abraham, Pierre-François Laterre, Jorge Garbino et al. · Critical Care Medicine · 2001 · 291 citations
Gökhan Yücel, Zhihan Zhao, Ibrahim El‐Battrawy et al. · Scientific Reports · 2017 · 159 citations · Full text